Publication: ASEAN Capacity for Vaccine Research and Development and Production: Malaysia Country Case Study
Loading...
Date
2023-06-16
ISSN
Published
2023-06-16
Author(s)
Editor(s)
Abstract
COVID-19 has devastated the ASEAN region, threatening two decades of human and economic development gains. With a population of more than 600 million, the region has reported more than 13 million COVID-19 cases as of October 2021, with Indonesia, the Philippines, Malaysia, and Thailand leading in number of confirmed cases. In the absence of effective treatment options, vaccination and preventative behaviors remain cornerstones for ASEAN governments to stop COVID-19’s spread, save lives, and revive economies. Despite rapid innovation and development of mRNA, viral vector, and protein subunit vaccine technology platforms, low and middle-income countries (LMICs) continue to struggle to access vaccines. ASEAN countries have remained net importers of essential vaccines, notwithstanding strong potential for local research and manufacture. Consequently, COVID-19 vaccination coverage varies widely, ranging from 10 percent in Myanmar to 80 percent in Singapore. These disparities render the region vulnerable to new variants, surges, and vaccine escape. To contain COVID-19 and respond to future pandemics, ASEAN must build strong regional capacity to develop, test, and scale up manufacture of vaccines, building on country-level strengths and avoiding duplication. Galvanizing ASEAN vaccine development and manufacturing efforts aligns with the November 2019 declaration of ASEAN leaders on regional vaccine security and self-reliance.
Link to Data Set
Citation
“World Bank. 2023. ASEAN Capacity for Vaccine Research and Development and Production: Malaysia Country Case Study. © World Bank. http://hdl.handle.net/10986/40375 License: CC BY-NC 3.0 IGO.”
Associated URLs
Associated content
Other publications in this report series
Journal
Journal Volume
Journal Issue
Collections
Related items
Showing items related by metadata.
Publication ASEAN Capacity for Vaccine Research and Development and Production(Washington, DC: World Bank, 2023-06-16)COVID-19 has had a devastating effect on the ASEAN region, which has recorded over 27 million cases of the virus. Access to COVID-19 vaccination has significantly reduced the spread of the disease and limited the number of severe COVID-19 cases, but it has also impacted routine immunization coverage. Countless strategies have been developed to ensure vaccine equity, which were swiftly translated from political assessment to practical action; however, they failed to address the sustained growth of the COVID-19 pandemic and the emergence of variants of concerns, requiring ongoing vaccine booster doses. The pandemic revealed weaknesses in ASEAN's regional vaccine capacity, including in research and development, manufacturing infrastructure and human resources, which made the region particularly vulnerable during COVID-19 surges, as it was highly dependent on vaccine imports. Despite the existence of an established framework for ASEAN collaboration on vaccines, there has been minimal coordination between member states to collectively procure COVID-19 vaccines. Initial consultations with various stakeholders involved in vaccination and equitable access in the ASEAN region highlighted several gaps related to ensuring a sustained supply of quality vaccines throughout the life cycle, as well as several critical areas that require immediate attention. The political commitment to address these issues has been shaped by the evolving pandemic scenarios. The ASEAN Vaccine Security and Self-Reliance (AVSSR) initiative was launched just before the COVID-19 pandemic began and was agreed upon and endorsed by the region's ten leaders during the 34th ASEAN Summit in November 2019. Future regional strategies, policies and plans must ensure consistency with this important ASEAN initiative.Publication ASEAN Vaccine Manufacturing Research Project(Washington, DC: World Bank, 2023-06-16)The COVID-19 pandemic has had a devastating effect on the ASEAN region, which has recorded over 27 million cases of the virus. Despite rapid development of a range of COVID-19 vaccines using innovative technologies, access to these vaccines has been a challenge, with manufacturing mostly concentrated in the US and Europe for high-value mRNA vaccines, and China and India for traditional platforms and high-volume production. Countries with domestic COVID-19 vaccine manufacturing capacity prioritized domestic vaccine requirements over foreign needs, putting countries with limited production capabilities at a disadvantage. ASEAN countries, which overall have made limited investments in research and development of vaccines and biologicals, were highly dependent on imports, resulting in heightened vulnerability during COVID 19 surges. Despite the existence of an established framework for ASEAN coordination on vaccines, there has been minimal coordination between member states to collectively procure COVID-19 vaccines. Consequently, ASEAN countries have experienced a common set of challenges in navigating the complex global vaccine market to ramp up COVID-19 vaccination. Leaders of ASEAN member states have recognized the need for the region to be self-sufficient in vaccine research and manufacturing to effectively address future pandemics and build regional vaccine security. ASEAN must build regional capacity to develop, test efficacy, and scale up manufacture of vaccines, building on existing country-level strengths and avoiding duplication.Publication ASEAN Regional Vaccine Manufacturing and Development(Washington, DC: World Bank, 2023-04-18)This report is organized into six chapters. The first chapter provides an introduction and presents a brief situation analysis of current research and development and manufacturing capacities in the region based on detailed desk review. The second chapter describes the importance of coordination in ensuring regional vaccine security and presents different complementary pathways for achieving the AVSSR vision. The third chapter comprehensively describes the vaccine value chain in the ASEAN region, covering both backward and forward integration aspects, including logistics and delivery. The fourth chapter describes strategic priorities relevant to regional vaccine eco-system development and describes existing strengths and weaknesses within selected ASEAN countries that could influence such development. The fifth chapter summarizes findings of an economic analysis of investing in late-stage clinical trials, manufacture, and regulatory strengthening for a limited set of priority diseases. A strong economic case is made for investing at the regional level compared to the national level by using cost benefit ratios. The concluding chapter summarizes feedback from key stakeholders in both public and private sectors and utilizes this feedback to present a way forward by listing specific tasks for ASEAN member state governments, the Secretariat, and the World Bank Group.Publication Investing in Vaccine Security in the ASEAN Region(Washington, DC: World Bank, 2024-06-20)Vaccine security and self-sufficiency have received increased global attention in the wake of the COVID-19 pandemic, as low- and middle-income countries were heavily dependent on high-income countries (HICs) and international organizations for vaccine supply, resulting in global competition for vaccines and huge inequities. Achieving vaccine security and self-sufficiency is of high importance to Southeast Asia. To achieve this goal, the Association of Southeast Asian Nations (ASEAN) established the ASEAN vaccine security and self-reliance (AVSSR) initiative. Building on the efforts of ASEAN leadership, the World Bank commissioned this study to estimate the public health and economic benefits arising from investments in AVSSR, specifically in vaccine research and development (R&D), manufacturing, and regulation. The study assumes that five ASEAN countries - Indonesia, Malaysia, the Philippines, Thailand, and Vietnam - make public and private investments to strengthen vaccine security. Applying a societal perspective, the study considers four different investments scenarios. Scenario 1 assumes that costs will be shared between these five countries and that these countries alone will benefit from the vaccine security efforts, while Scenario 2 assumes health and economic benefits to the other five ASEAN countries (Brunei, Cambodia, Laos, Myanmar, and Singapore) as well. Scenario 3 assumes that only one country of 100 million people produces and prioritizes vaccines for its population, while Scenario 4 assumes a pandemic of COVID19 magnitude. The findings of the study clearly show that regional investments in clinical trials, manufacturing and regulatory capacity building will have a substantial public health impact and offer high benefit-cost ratios. Findings from this study align with the AVSSR Strategic and Action Plan 2021-2025, which makes the case for stronger regional vaccine capacity, enhanced vaccine manufacturing capacity, and human resource development to realize the goal of self-reliance.Publication Regional Vaccine Manufacturing and Development(Washington, DC: World Bank, 2023-06-16)COVID-19 has had a devastating effect on the ASEAN region, which has recorded over 27 million cases of the virus. Despite rapid development of a range of COVID-19 vaccines using innovative technologies, access to these vaccines has been a challenge, with manufacturing mostly concentrated in the US and Europe for high-value mRNA vaccines, and China and India for traditional platforms and high-volume production. Countries with domestic COVID-19 vaccine manufacturing capacity prioritized domestic vaccine requirements over foreign needs, putting countries with limited production capabilities at a disadvantage. ASEAN countries, which overall have made limited investments in research and development of vaccines and biologicals, were highly dependent on imports, resulting in heightened vulnerability during COVID-19 surges. Despite the existence of an established framework for ASEAN coordination on vaccines, there has been minimal coordination between member states to collectively procure COVID-19 vaccines. Consequently, ASEAN countries have experienced a common set of challenges in navigating the complex global vaccine market to ramp up COVID-19 vaccination. Leaders of ASEAN member states have recognized the need for the region to be self-sufficient in vaccine research and manufacturing to effectively address future pandemics and build regional vaccine security. ASEAN must build regional capacity to develop, test efficacy, and scale up manufacture of vaccines, building on existing country-level strengths and avoiding duplication. While some evidence on regional vaccine manufacturing capacity for ASEAN exists, there has been limited research on the technical, operational, financing and strategic partnership opportunities that exist in the region and might be leveraged to advance regional vaccine security. To address this knowledge gap, the United Kingdom Foreign, Commonwealth and Development Office (UK FCDO) and the World Bank initiated the ASEAN Vaccine Development and Manufacturing Research Project. This project complements the ASEAN Vaccine Security and Self-Reliance (AVSSR) Initiative and the Coalition for Epidemic Preparedness Innovations (CEPI) 2021 plan, and supports the November 2019 declaration of ASEAN leaders on regional vaccine security and self-reliance.
Users also downloaded
Showing related downloaded files
Publication Qualitative Study of the Feasibility of HPV Vaccine Delivery to Young Adolescent Girls in Vietnam(BioMed Central, 2014-06-05)Introduction of human papillomavirus (HPV) vaccine in national programs has proceeded apace since 2006, mostly in high-income countries. Recently concluded pilots of HPV vaccination in low-income countries have provided important lessons learned for these settings; however, rigorous evaluations of the feasibility of these delivery strategies that effectively reach young adolescents have been few. This paper presents results from a qualitative evaluation of a demonstration program which implemented school-based and health center–based HPV vaccinations to all girls in grade 6, or 11 years of age, for two years in four districts of Vietnam.Publication Immunization Finance Toolkit : A Resource for Policy-Makers and Program Managers(World Bank, Washington, DC, 2010-12)Financing is a critical component of a sustainable Immunization program. The Immunization Financing Toolkit is a series of short briefs on different options for financing national immunization programs and vaccines. It is intended to serve as a resource for program managers and decision---makers in ministries of health, planning, and finance. The Toolkit brings together the most up---to---date knowledge on the characteristics of various types of= financing mechanisms as well as information on how the mechanisms are being implemented in practice, their potential benefits, and their limitations. Where possible, case studies on specific financing options are included. The field of immunization financing continues to evolve and the Toolkit will therefore be web---based and easily downloaded from the internet. As a web---based tool, the Toolkit contains links to other relevant websites for further understanding. The Toolkit is also available on a CD Rom. This version of the Toolkit is an update of the Immunization Financing Options produced by the Global Alliance for Vaccines and Immunization (GAVI Alliance) in 2001. Health sector funding and management have evolved over the last decade, making the previous document out---of---date. New and innovative financing mechanisms to support immunization and the health sector have been developed and the types and costs of vaccines have changed. In addition, policy---makers and development partners have become much more knowledgeable about health financing.Publication Global Economic Prospects, January 2021(Washington, DC: World Bank, 2021-01-05)Although the global economy is emerging from the collapse triggered by COVID-19, the recovery is likely to be subdued, and global GDP is projected to remain well below its pre-pandemic trend for a prolonged period. Several risks cloud the outlook, including those related to the pandemic and to rapidly rising debt. The pandemic has further diminished already-weak growth prospects for the next decade. Decisive policy actions will be critical in raising the likelihood of better growth outcomes while warding off worse ones. Immediate priorities include supporting vulnerable groups and ensuring a prompt and widespread vaccination process to bring the pandemic under control. Although macroeconomic policy support will continue to be important, limited fiscal policy space amid high debt highlights the need for an ambitious reform agenda that bolsters growth prospects. To address many of these challenges, global cooperation will be key.Publication Pharmaceuticals in Latin America and the Caribbean(World Bank, Washington, DC, 2022-01-03)Pharmaceutical products have contributed to longer life expectancy and better quality of life in Latin America and the Caribbean. However, they often account for a significant share of household expenditures, especially among the poor and those facing catastrophic health shocks. And they are not always accessible, as dramatically exposed by the Covid-19 pandemic. This mixed record can be linked to the workings of the pharmaceutical sector, an issue that has not received much attention in policy discussions. This paper identifies the sector’s key domestic and foreign players, and analyzes its local output, international trade, and price levels. It also documents government policies, including intellectual property rights, regulatory oversight, and public procurement. An important contribution of the paper is to show the significant scientific capacity of the region, especially in relation to biological products - including vaccines - whose intrinsic heterogeneity challenges intellectual property rights protection. Based on this diagnosis, the paper flags three sets of issues for policy makers to consider. Relatively uncontroversial measures include strengthening regulatory authorities, promoting the use of generics, and upgrading public procurement. Other areas, such as supporting R and D and regulating prices, involve tradeoffs. Finally, there are strategic choices to be made, with some countries in the region favoring stringent intellectual property rights, while others support national champions or rely on state entrepreneurship.Publication ASEAN Regional Vaccine Manufacturing and Development(Washington, DC: World Bank, 2023-04-18)This report is organized into six chapters. The first chapter provides an introduction and presents a brief situation analysis of current research and development and manufacturing capacities in the region based on detailed desk review. The second chapter describes the importance of coordination in ensuring regional vaccine security and presents different complementary pathways for achieving the AVSSR vision. The third chapter comprehensively describes the vaccine value chain in the ASEAN region, covering both backward and forward integration aspects, including logistics and delivery. The fourth chapter describes strategic priorities relevant to regional vaccine eco-system development and describes existing strengths and weaknesses within selected ASEAN countries that could influence such development. The fifth chapter summarizes findings of an economic analysis of investing in late-stage clinical trials, manufacture, and regulatory strengthening for a limited set of priority diseases. A strong economic case is made for investing at the regional level compared to the national level by using cost benefit ratios. The concluding chapter summarizes feedback from key stakeholders in both public and private sectors and utilizes this feedback to present a way forward by listing specific tasks for ASEAN member state governments, the Secretariat, and the World Bank Group.